Dr. Perez-Soler on Treatment Options for NSCLC

Roman Perez-Soler, MD
Published Online: Tuesday, Feb 14, 2012

Roman Perez-Soler, MD, Chairman, Department of Oncology, Montefiore Medical Center, Albert Einstein College of Medicine of Yeshiva University, talks about the recent advances in treatment options for non-small cell lung cancer (NSCLC).

Perez-Soler states that targeted agents represent the most dramatic changes in the treatment of NSCLC. New agents are available that target subgroups with molecular alterations in EGFR and ALK. These alterations are driver mutations in tumor cells and as a result render high response rates.

Despite the initial response to a medication most tumors will eventually develop resistance. The next step for research is to understand how these tumors develop these resistance mechanisms.

Roman Perez-Soler, MD, Chairman, Department of Oncology, Montefiore Medical Center, Albert Einstein College of Medicine of Yeshiva University, talks about the recent advances in treatment options for non-small cell lung cancer (NSCLC).

Perez-Soler states that targeted agents represent the most dramatic changes in the treatment of NSCLC. New agents are available that target subgroups with molecular alterations in EGFR and ALK. These alterations are driver mutations in tumor cells and as a result render high response rates.

Despite the initial response to a medication most tumors will eventually develop resistance. The next step for research is to understand how these tumors develop these resistance mechanisms.


View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: 16th Annual International Lung Cancer Congress®Oct 06, 20162.0
Medical Crossfire®: Mutational Testing Through Multiple Lines of NSCLC TherapyJan 29, 20171.5
Publication Bottom Border
Border Publication